Metformin attenuates colitis via blocking STAT3 acetylation by reducing acetyl-CoA production
This study identifies acetyl-CoA-dependent STAT3 acetylation as a novel mechanism through which metformin ameliorates intestinal inflammation and barrier dysfunction. These findings not only advance our understanding of metformin's immunomodulatory properties but also highlight the therapeutic potential of targeting acetyl-CoA metabolism in UC.
Authors
- Zixuan Xiang (ORCID: https://orcid.org/0000-0003-3818-0599)
- Weiguo Dong (ORCID: https://orcid.org/0000-0002-4228-6508)
- Xiaoli Wang (ORCID: https://orcid.org/0000-0002-9388-0734)
- Miao Xu (ORCID: https://orcid.org/0000-0001-7091-4199)
- Jixiang Zhang (ORCID: https://orcid.org/0000-0002-3742-8057)
- Haodong He
- Xiangyun Li (ORCID: https://orcid.org/0000-0002-7846-3561)
- Xiaohan Wu (ORCID: https://orcid.org/0009-0009-5653-6529)
- Cheng Yong Tan (ORCID: https://orcid.org/0000-0002-5046-0756)
Institutions
- Wuhan University (CN)
- Renmin Hospital of Wuhan University (CN)
- China Medical University (CN)
Publication Details
- Journal
- Journal of Advanced Research
- Published
- 2025-04-02
- DOI
- https://doi.org/10.1016/j.jare.2025.03.058
- Citations
- 7
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 12.72
Funders
- National Natural Science Foundation of China
- National Key Research and Development Program of China